sandimmun neoral 50 mg
farmagon - ciklosporin - kapsel, myk - 50 mg
sandimmun neoral 100 mg
farmagon - ciklosporin - kapsel, myk - 100 mg
sandimmun neoral 100 mg
farmagon - ciklosporin - kapsel, myk - 100 mg
sandimmun neoral 100 mg
farmagon - ciklosporin - kapsel, myk - 100 mg
sandimmun neoral 100 mg
farmagon - ciklosporin - kapsel, myk - 100 mg
sandimmun neoral 100 mg
farmagon - ciklosporin - kapsel, myk - 100 mg
warfarin orion 2.5 mg
orion corporation - espoo - warfarinnatrium - tablett - 2.5 mg
alunbrig
takeda pharma a/s - brigatinib - karsinom, ikke-småcellet lunge - antineoplastiske midler - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.
ayvakyt
blueprint medicines (netherlands) b.v. - avapritinib - gastrointestinal stromal tumors - andre cytostatika, protein kinase hemmere - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.
copiktra
secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastiske midler - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies. follicular lymphoma (fl) that is refractory to at least two prior systemic therapies.